MarketCapExport financials
Genocea Biosciences (GNCA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Genocea Biosciences Balance Sheet 2021-2011 | GNCA
Brief overview of Genocea Biosciences's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2017 to 2021.
Assets rose from $17.5 million to $56 million, a gain of +220%, while CAGR was about 33.8%. The balance sheet expanded rapidly.
Growth in the asset base was not matched by liabilities: +220% versus +22.7%. The balance sheet moved in a more conservative direction.
The equity ratio is 48.4% versus -34.6% five periods ago. Capitalization remains workable.
Negative net debt of -$30.7 million means cash holdings are larger than debt obligations.
Cash accounts for 66.4% of assets versus 70.2% initially. The change indicates the degree of financial flexibility.
Retained earnings remain negative at -$407.9 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
What the balance sheet shows
The indicators point to a strong balance sheet position for Genocea Biosciences: funding is balanced and liability risks appear controlled.
Annual Balance Sheet Genocea Biosciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-30.7 M | -64.3 M | -25.7 M | -11.5 M | 2.04 M | -10.5 M | -782 K | -8.67 M | -2.41 M | -9.15 M | -5.54 M |
Long Term Debt |
4.15 M | 13.9 M | 13.4 M | 9.56 M | 7.65 M | 13.8 M | 16.5 M | 11.4 M | 8.93 M | 2.37 M | 51 K |
Long Term Debt Current |
2.35 M | 1.59 M | 990 K | 5.26 M | 6.66 M | 3.15 M | - | - | 861 K | - | - |
Total Non Current Liabilities |
- | 64.5 M | 21.3 M | 13 M | 7.76 M | 14 M | 16.5 M | 12.1 M | 9.84 M | 3.02 M | 390 K |
Total Current Liabilities |
18.7 M | 25 M | 6.28 M | 10.7 M | 15.8 M | 10.4 M | 5.97 M | 5.84 M | 4.49 M | - | - |
Total Liabilities |
28.9 M | 89.5 M | 27.6 M | 23.8 M | 23.5 M | 24.4 M | 22.5 M | 17.8 M | 14.3 M | 7.23 M | 2.65 M |
Deferred Revenue |
1.7 M | 1.64 M | - | - | - | - | 235 K | 555 K | 12 K | - | 23 K |
Retained Earnings |
-408 M | -375 M | -331 M | -292 M | -264 M | -207 M | -158 M | -115 M | -80.1 M | -58.4 M | -43.6 M |
Total Assets |
56 M | 98.5 M | 52.6 M | 31.1 M | 17.5 M | 69.9 M | 112 M | 50.3 M | 15.8 M | 13.5 M | 6.94 M |
Cash and Cash Equivalents |
37.1 M | 79.8 M | 40.1 M | 26.4 M | 12.3 M | 27.4 M | 17.3 M | 20.1 M | 12.2 M | 11.5 M | - |
Book Value |
27.1 M | 8.98 M | 25 M | 7.34 M | -6.05 M | 45.5 M | 89.7 M | 32.5 M | 1.43 M | 6.3 M | 4.29 M |
Total Shareholders Equity |
27.1 M | 8.98 M | 25 M | 7.34 M | -6.05 M | 45.5 M | 89.7 M | 32.5 M | -80.1 M | -58.4 M | - |
All numbers in USD currency
Quarterly Balance Sheet Genocea Biosciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 2.95 M | 4.15 M | 5.33 M | 6.49 M | 7.65 M | - | - | - | 5.82 M | 13.4 M | 8.04 M | 11.1 M | 8.01 M | 9.56 M | 11.1 M | 12.5 M | 13.9 M | 7.65 M | 9.24 M | 10.8 M | 12.3 M | 13.8 M | 15.3 M | 16.7 M | 16.6 M | 16.5 M | 10.6 M | 11.6 M | 10.5 M | 11.4 M | 6.25 M | 7.15 M | 8.04 M | 8.93 M | 8.93 M | 8.93 M | 8.93 M | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | 26.4 M | 28.9 M | 27.1 M | 73.3 M | 82.2 M | 89.5 M | 86 M | 32.5 M | 32.2 M | 27.6 M | 27.9 M | 32.3 M | 29.6 M | 23.8 M | 33.2 M | 35.2 M | 41.9 M | 23.5 M | 24.4 M | 23.4 M | 22.6 M | 24.4 M | 22.5 M | 21 M | 21.7 M | 22.5 M | 19 M | 18.1 M | 18.7 M | 17.8 M | 14.8 M | 12.8 M | 12.8 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | 1.56 M | 1.7 M | - | 1.64 M | 1.64 M | 1.64 M | 1.64 M | 1.09 M | 1.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 235 K | 457 K | 670 K | 556 K | 555 K | 766 K | 30 K | 12 K | 12 K | 12 K | 12 K | 12 K | - | - | - | - | - | - | - | - |
Retained Earnings |
- | - | - | -424 M | -408 M | -395 M | -391 M | -387 M | -375 M | -360 M | -355 M | -344 M | -331 M | -322 M | -314 M | -308 M | -292 M | -292 M | -285 M | -280 M | -264 M | -253 M | -237 M | -221 M | -207 M | -191 M | -179 M | -168 M | -158 M | -148 M | -138 M | -128 M | -115 M | -104 M | -94.6 M | -87.5 M | -80.1 M | -80.1 M | -80.1 M | -80.1 M | - | - | - | - | - | - | - | - |
Total Assets |
- | - | - | 38.8 M | 56 M | 64.9 M | 77.4 M | 83.9 M | 98.5 M | 106 M | 40.5 M | 45.2 M | 52.6 M | 59.3 M | 70.8 M | 35.8 M | 31.1 M | 39.7 M | 49 M | 56.5 M | 17.5 M | 28 M | 42.6 M | 55.6 M | 69.9 M | 82.9 M | 92.9 M | 103 M | 112 M | 118 M | 78.7 M | 88.4 M | 50.3 M | 55.8 M | 61.8 M | 68.2 M | 15.8 M | 15.8 M | 15.8 M | 15.8 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
- | - | - | 20.1 M | 37.1 M | 48.9 M | 60.4 M | 66 M | 79.8 M | 87.6 M | 22.1 M | 26.5 M | 40.1 M | 46.6 M | 58.7 M | 29 M | 26.4 M | 34.5 M | 44.2 M | 51.2 M | 12.3 M | 22 M | 35.2 M | 34.1 M | 27.4 M | 26.4 M | 18.3 M | 37.7 M | 17.3 M | 42.8 M | 49.6 M | 57.5 M | 20.1 M | 25.1 M | 32.1 M | 65.8 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 11.5 M | - | - | - | 5.74 M | - | - | - |
Book Value |
- | - | - | 12.4 M | 27.1 M | 37.8 M | 4.06 M | 1.76 M | 8.98 M | 20.2 M | 8.04 M | 13 M | 25 M | 31.4 M | 38.4 M | 6.24 M | 7.34 M | 6.5 M | 13.9 M | 14.6 M | -6.05 M | 3.69 M | 19.2 M | 33.1 M | 45.5 M | 60.3 M | 71.9 M | 81 M | 89.7 M | 98.9 M | 60.7 M | 69.7 M | 32.5 M | 41 M | 49 M | 55.4 M | 1.43 M | 1.43 M | 1.43 M | 1.43 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
- | - | - | 12.4 M | 27.1 M | 37.8 M | 4.06 M | 1.76 M | 8.98 M | 20.2 M | 8.04 M | 13 M | 25 M | 31.4 M | 38.4 M | 6.24 M | 7.34 M | 6.5 M | 13.9 M | 14.6 M | -6.05 M | 3.69 M | 19.2 M | 33.1 M | 45.5 M | 60.3 M | 71.9 M | 81 M | 89.7 M | 98.9 M | 60.7 M | 69.7 M | 32.5 M | 41 M | 49 M | 55.4 M | -80.1 M | -80.1 M | -80.1 M | -80.1 M | -58.4 M | - | - | - | -43.6 M | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Genocea Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
